# Research Peptides US — Research Peptide Fundamentals research peptides

> A blunt, citation-anchored look at five widely-discussed research peptides — BPC-157, KPV, NAD+, retatrutide, and tirzepatide — across the US research-peptide landscape. What the evidence shows and what it doesn't.

A practical rundown of what US research communities are actually studying right now — tissue repair, gut inflammation, cellular energy, and two metabolic receptor agonists — with the evidence sorted from the noise.

## The short version

Research Peptides US covers five peptides that show up constantly in research forums, supplement shelves, and clinical literature, and treats them the same blunt way: what does the published evidence actually say, and where does it stop? A **peptide** is just a short chain of amino acids — the building blocks of protein — small enough to be made in a lab and, in some cases, potent enough to change how the body signals itself.

The five here span very different territory. **BPC-157** is a gut-derived peptide studied mostly in rats for tissue repair. **KPV** is a tiny anti-inflammatory fragment that has never been tested in a single published human trial. **NAD+** is a coenzyme every cell already runs on, marketed as a supplement and an IV drip. **Retatrutide** and **tirzepatide** are metabolic receptor agonists — tirzepatide is FDA-approved, retatrutide is not, and both come from the same incretin-pharmacology family that has reshaped obesity and diabetes research over the past several years.

This site does not sell anything, does not tell anyone what dose to take, and does not pretend animal data or a forum thread is the same thing as a clinical trial. It reports what was studied, in whom, and how far that evidence honestly reaches.

## The US research-peptide landscape at a glance

Walk into any US research-peptide discussion and these five names come up constantly, for different reasons. BPC-157 gets requested for tendons, joints, and gut issues. KPV shows up in gut-health and inflammation threads despite having zero human trial data behind it. NAD+ gets sold in IV bars and supplement aisles on a longevity pitch. Retatrutide and tirzepatide dominate the weight-loss and metabolic conversation, with retatrutide treated as the "next" tirzepatide even though it hasn't cleared Phase 3.

What ties them together isn't a shared mechanism — it's a shared gap between hype and evidence maturity. Two of the five (tirzepatide, and to a lesser extent NAD+'s precursor forms) have real human trial programs behind them. Two (BPC-157, retatrutide) have thin-to-moderate human data and heavy animal or early-phase backing. One (KPV) has no human data whatsoever. Reading them side by side, rather than one at a time on a vendor's product page, is the only way to see that gap clearly. This site's [comparison page](/compare) puts the five head to head on exactly that basis.

## What are research peptides, and what this site won't do

"Research peptide" is the label suppliers use for a peptide sold for laboratory use, not human consumption — meaning it hasn't gone through FDA approval, isn't manufactured under pharmaceutical quality control, and carries no verified purity or dosing standard outside a formal study. Some of the compounds on this desk (tirzepatide) have graduated to approved-medicine status through full clinical trial programs. Most have not, and some (KPV) have barely entered human study at all.

This site describes what the literature says a peptide does in animals, in cells, or in the small number of humans who have been formally studied — and separately, what people in research-use communities report anecdotally, clearly labeled as such. It never recommends a dose, a use, or a source. It does not sell peptides, does not link to vendors, and does not pretend a Reddit thread is a clinical trial. Every specific number on this site — a percentage, a half-life, a trial size — traces back to a [numbered citation](/references).

---

A no-nonsense literature rundown on research peptides — straight evidence, no sales, no dosing advice.